AKT1 mutation
|
Triple Negative Breast Cancer
|
AKT1 mutation
|
Triple Negative Breast Cancer
|
RG7440 Sensitive: B - Late Trials
|
RG7440 Sensitive: B - Late Trials
|
AKT1 mutation
|
CRC
|
AKT1 mutation
|
CRC
|
atezolizumab + cobimetinib Sensitive: B - Late Trials
|
atezolizumab + cobimetinib Sensitive: B - Late Trials
|
AKT1 mutation
|
Breast Cancer
|
AKT1 mutation
|
Breast Cancer
|
ribociclib Sensitive: B - Late Trials
|
ribociclib Sensitive: B - Late Trials
|
AKT1 mutation
|
Endometrial Cancer
|
AKT1 mutation
|
Endometrial Cancer
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
AKT1 mutation
|
Prostate Cancer
|
AKT1 mutation
|
Prostate Cancer
|
AZD5363 Sensitive: D – Preclinical
|
AZD5363 Sensitive: D – Preclinical
|